Scientists probe hidden immune cells behind hepatitis b vaccine protection
NCT ID NCT06876467
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at how the hepatitis B vaccine triggers T cells, a key part of the immune system. Researchers will test blood from 115 healthy adults 5 to 10 weeks after vaccination to see if they have T cells that recognize the hepatitis B virus. The goal is to understand why some people maintain protection longer and how to improve vaccines.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- hepatitis B vaccine
- What this could lead to
- If successful, this study could help improve hepatitis B vaccines by revealing how T cells contribute to long-lasting protection.
- What could go wrong
- This is an observational study, not a treatment trial. It only measures immune responses in a small group of healthy adults, so results may not apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B VACCINATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Saint Louis AP-HP
RECRUITINGParis, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a sugar in your drink quietly weaken your Gut's defenses?
- Scientists probe immune cell shifts in ICU patients to unlock sepsis secrets
- Probiotics may supercharge COVID-19 shots, study finds
- Altitude pill may also fight inflammation, early study hints
- Ebola vaccine immunity under the microscope: how long does protection last?
- New combo therapy aims to fight advanced colorectal cancer